Shane Olwill - 30 Aug 2021 Form 4 Insider Report for PIERIS PHARMACEUTICALS, INC. (PVLA)

Role
Chief Development Officer
Signature
/s/ Megan Gates, Attorney-in-Fact
Issuer symbol
PVLA
Transactions as of
30 Aug 2021
Net transactions value
-$138,012
Form type
4
Filing time
01 Sep 2021, 16:38:01 UTC
Previous filing
03 Aug 2021
Next filing
24 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PIRS Common Stock Options Exercise $58,368 +38,400 +828% $1.52* 43,038 30 Aug 2021 Direct
transaction PIRS Common Stock Sale $46,000 -9,200 -21% $5.00* 33,838 30 Aug 2021 Direct
transaction PIRS Common Stock Sale $150,380 -29,200 -86% $5.15* 4,638 30 Aug 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PIRS Stock Option (right to buy) Options Exercise $0 -38,400 -38% $0.000000 61,600 30 Aug 2021 Common Stock 100,000 $1.52 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.07 to $5.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F2 The option has fully vested.